Telix and United Imaging Announce Strategic Theranostics Collaboration
Rhea-AI Summary
Telix (TLX) and United Imaging signed a U.S. Memorandum of Understanding for a strategic research collaboration in integrated theranostics.
The partners plan to combine Telix’s molecular imaging products with United Imaging’s scanner, software, connectivity and AI platforms, initially focusing on TLX101-Px (Pixclara, Floretyrosine F 18) in the U.S.
Positive
- None.
Negative
- None.
News Market Reaction – TLX
In the Jun 2 session, TLX declined 2.76%, reflecting a moderate negative market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 27 | Conference participation | Neutral | +1.8% | Announcement of CEO presentations at major healthcare investor conferences. |
| May 18 | Clinical trial update | Positive | -1.3% | Completion of IPAX-2 enrollment and dose confirmation in first-line glioblastoma. |
| May 15 | Collaboration agreements | Positive | -2.8% | LOIs to explore PSMA-PET imaging with minimally invasive prostate cancer therapies. |
| May 04 | Clinical data publication | Positive | -1.0% | New ZIRCON analysis showing strong TLX250-Px performance in kidney cancer diagnosis. |
| Apr 30 | Regulatory milestone | Positive | +2.4% | European MAA acceptance and assessment start for TLX101-Px in glioma imaging. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive development and collaboration news has often met with muted or negative next-day moves, though regulatory milestones like MAA acceptance have seen more supportive price reactions.
Over the last few months, Telix has highlighted multiple clinical and strategic milestones. On Apr 30, the MAA acceptance for TLX101-Px in Europe coincided with a +2.36% move. Subsequent data and collaboration updates on TLX250-Px and PSMA-PET imaging (May 4 and May 15) saw modest share price declines despite positive-sounding content. The IPAX-2 enrollment completion on May 18 was similarly followed by a -1.26% move. Conference participation news on May 27 produced a mild +1.78% gain. Today’s U.S. theranostics collaboration fits this pattern of ongoing partnering and pipeline development.
Key Terms
theranostics medical
radiopharmaceutical medical
molecular imaging medical
ai technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Partnership to evaluate Telix’s innovative precision medicine products and candidates in combination with United Imaging’s advanced scanner platforms.
- Initial focus on TLX101-Px (Pixclara®1, Floretyrosine F 18) in the U.S.
- Framework to support potential co-development, validation, and deployment of integrated theranostics workflows.
MELBOURNE, Australia and INDIANAPOLIS and HOUSTON, June 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) and United Imaging Healthcare North America, Inc. (“United Imaging”) today announce the signing of a Memorandum of Understanding (MOU) to evaluate a strategic research collaboration in the United States (U.S.) focused on advancing integrated theranostics solutions.
The companies will evaluate the combination of United Imaging’s scanner platforms, software, connectivity and AI capabilities with Telix’s molecular imaging portfolio and validated clinical protocols. The collaboration will explore how a unified approach can drive theranostic workflow efficiencies and standardization by:
- Enhancing integration between imaging systems and radiopharmaceutical workflows.
- Enabling consistent, protocol-driven imaging performance across systems and sites.
- Supporting treatment planning, monitoring, and longitudinal patient management.
- Advancing data-driven and AI-enabled clinical decision support tools.
Jeffrey M. Bundy, Ph.D., President & Chief Commercial Officer, United Imaging Healthcare North America, said: “Theranostics represents a fundamental shift toward more integrated and personalized cancer care. Through this collaboration with Telix, we aim to explore how deeply integrated imaging, AI, and radiopharmaceutical workflows can be combined to support routine clinical use at scale.”
Kevin Richardson, CEO, Telix Precision Medicine, added, “Realizing the full potential of theranostics requires close alignment between state-of-the-art scanners, integrated software solutions, and radiopharmaceutical innovation. By working with United Imaging, we are exploring new ways to deliver more seamless, data-driven workflow solutions that can support clinicians in their decision making, leading to better patient outcomes.”
The collaboration will initially focus on TLX101-Px (Pixclara®1, Floretyrosine F 18) in the U.S, with potential expansion into additional markets, and other Telix products and product candidates, subject to mutual agreement. Early efforts will include scanning protocol optimization, workflow support tools development and validation, and launching pilot programs aligned with high-impact clinical applications.
About TLX101-Px
TLX101-Px is a PET imaging candidate, which has been granted Fast Track and Orphan Drug designations by the FDA for the characterization of recurrent or progressive glioma from treatment related changes. In April 2026, the U.S. Food and Drug Administration (FDA) accepted Telix’s New Drug Application (NDA) for review, and assigned a PDUFA2 goal date of September 11, 2026.
TLX101-Px targets membrane transport proteins known as L-type amino acid transporters 1 and 2 (LAT1 and LAT2). This enables TLX101-Px to be potentially utilized as a patient selection and response assessment tool for Telix’s LAT1-targeting therapy candidate TLX101-Tx (131I-iodofalan), currently under investigation in the pivotal IPAX-BrIGHT trial in patients with recurrent glioblastoma3. TLX101-Px has not received a marketing authorization in any jurisdiction.
About United Imaging
United Imaging develops and produces advanced medical products, digital healthcare solutions, and intelligent systems that support the entire imaging diagnosis and treatment process. Founded in 2011, United Imaging operates subsidiaries and R&D centers worldwide. Its North American headquarters in Houston includes corporate offices, a manufacturing facility, product showroom, service training center, and service parts distribution center. Guided by its mission of Equal Healthcare for All™, United Imaging is committed to expanding access to high-quality medical imaging and driving meaningful progress in healthcare.
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
| Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com | Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com | Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com |
| Telix Media Eliza Schleifstein 917.763.8106 (Mobile) Eliza@schleifsteinpr.com | United Imaging (U.S.) Media Krista K. Stein 212.920.9694 (Mobile) Krista.stein@united-imaging.com | |
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
__________________________________
1 Brand name subject to final regulatory approval.
2 Prescription Drug User Fee Act.
3 ClinicalTrials.gov ID: NCT07100730.
